Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial

Sacubitril/Valsartan in Pediatric Heart Failure (PANORAMA-HF): A Randomized, Multicenter, Double-Blind Trial

Shaddy R,Burch M,Kantor P,Solar-Yohay S,Garito T,Zhang S,Kocun M,Mao C,Cilliers A,Wang X,Canter C,Rossano J,Wallis G,Menteer J,Daou L,Kusa J,Tokel K,Dilber D,Xu Z,Xiao T,Halnon N,Daly K,Bock M,Zuckerman W,Singh T,Chakrabarti M,Levitas A,Senni M,Grutter G,Kim G,Song J,Lee H,Chen C,Sanchez-de-Toledo J,Law Y,Wanitkun S,Cui Y,Anjos R,Mese T,Bonnet D,Ablonczy L,Aggarwal N,Agnoletti G,AlHabdan M,Amedro P,Ameduri R,Alberto Annoni G,Asante-Korang A,Audi N,Ballweg J,Berger F,Bosaleh M,Boyle G,Castaldi B,Chag M,Chaloupecky V,Chehab G,Conway J,Daehnert I,Di Bernardo S,Dittrich S,Dogan E,Donti A,Durongpisitkul K,Favilli S,Feingold B,Garcia-Guereta L,Gil-Villanueva N,Glass L,Gomez-Guzman E,Gorenflo M,Gran F,Hirata Y,Hirono K,Hoshino K,Hsieh K,Hussain M,Inuzuka R,Ishido M,Jeewa A,Johnson J,Jokinen E,Won Jung J,Kaneva-Nencheva A,Kaufman B,Kochilas L,Kumar S,Lal A,Viktorovna Leontyeva I,Lin I,Lytrivi I,Malcic I,Marinho da Silva A,Medrano Lopez C,Milanesi O,Deanne Miyamoto S,Motomura H,Odri Komazec I,Ono H,Pacileo G,Mark Payne R,Ramakrishnan S,Riggi C,Rusconi P,Sabiniewicz R,Salaymeh K,Schumacher K,Schweigmann U,Seguela P,Shih R,Singh R,Yurievna Sitnikova M,Spicer R,Stiller B,Sugiyama H,Sundararaghavan S,Takeda A,Thambo J,Trigo Pereira C,Ulger Tutar Z,Vaughn G,Velez H,Vignati G,Wang J,Wang J,Yasuda K,Ziolkowska L,Zuhlke L

Source :

2024 Nov 26

Pmid / DOI:

10.1161/CIRCULATIONAHA.123.066605

Abstract

BACKGROUNDSacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to

Voir la publication

Toutes les publications